Durvalumab Mesothelioma, Promising Results For Durvalumab Plus Chemotherapy In Patients With Malignant Pleural Mesothelioma Cancer Therapy Advisor

The immunotherapy drug durvalumab imfinzi is an immune checkpoint inhibitor.

Jacoby miles instagram. Currently there is one clinical trial of durvalumab for mesothelioma in phase ii. The maximum duration of durvalumab treatment was 12 months from the start of therapy. Odwyer md ceo and chair precog llc.

This is a remarkable result in mesothelioma and warrants confirmation in a randomised phase three trial which is already in the planning said peter j. If treatment in these clinical trials proves safe and effective durvalumab could be approved to treat this rare and aggressive cancer. This is a remarkable result in mesothelioma and warrants confirmation in a randomized phase three trial which is already in the planning said peter j.

Odwyer md ceo and chair precog llc pictured left. In the first reported trial of an immune checkpoint inhibitor with chemotherapy in patients with treatment naive malignant pleural mesothelioma durvalumab imfinzi in combination with cisplatin and pemetrexed alimta demonstrated clinical activity and tolerability according to a study published in the lancet oncology. Dream is an open label single arm multi centre phase ii trial with a safety run in designed to determine the activity safety and tolerability of durvalumab combined with cisplatin and pemetrexed as first line therapy in malignant pleural mesothelioma mpm.

The maximum duration of durvalumab treatment was 12 months from the start of therapy. Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma dream3r the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. One of the benefits of this trial is that durvalumab reactivates the immune response to detect cancer.

Chemotherapy naive patients with mpm of all. 1 there is already emerging evidence of the effectiveness of the. Mesothelioma cells use pd l1 to protect themselves from immune system attack.

Durvalumab is part of eight different clinical trials in various phases and combinations involving mesothelioma. These drugs work by blocking the protein pd l1. Mesothelioma is now being tested in similar clinical trials.

This trial is testing a combination of durvalumab with chemotherapy. The lung institute at baylor college of medicine in houston has been studying its effectiveness in combination with surgery both as a single agent and alongside tremelimumab another immunotherapy drug. Single arm phase 2 study evaluating the efficacy and safety of first line durvalumab plus chemotherapy in malignant pleural mesothelioma.